• linkedin
  • Increase Font
  • Sharebar

    Testosterone safety, efficacy data on Peyronie's treatment among sexual dysfunction research

    This article is part of the State of Urology 2014

    John J. Mulcahy, MD, PhDDr. MulcahyThe safety of testosterone replacement therapy (TRT) has been the subject of two recently published studies, which were followed by a January 2014 FDA announcement that the agency is investigating the risk of stroke, heart attack, and death in men taking TRT. Additional data on the safety of TRT, including its use in men following radical prostatectomy, will be presented at the AUA meeting, said John J. Mulcahy, MD, PhD, a sexual medicine specialist in private practice in Madison, AL.

    Dr. Mulcahy recommended that urologists keep an eye out for data on the efficacy of collagenase clostridium histolyticum (XIAFLEX), which was approved for the treatment of Peyronie’s disease late last year, and the erectile dysfunction drug avanafil (Stendra). Another noteworthy study will examine penile implant ectopic reservoir placement after robotic radical prostatectomy, he said.

    His specific abstract recommendations are as follows:

    PD22-02: Meaningful Change in Peyronie’s Disease Following Treatment With Collagenase Clostridium Histolyticum: Results From Two Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies
    Wayne J.G. Hellstrom

    PD20-05: Cost effectiveness of acute insertion of malleable penile prosthesis for refractory ischemic priapism in public hospital setting
    Michael J. Belsante

    MP48-02: Exercise improves the effect of testosterone replacement therapy and the durability of response after cessation of treatment
    Min Gu Park

    MP48-06: Hypogonadal men taking clomiphene citrate report similar satisfaction compred to men on testosterone replacement therapy
    Ranjith Ramasamy

    MP48-08: Safety of Testosterone Therapy in Men with Prostate Cancer
    Ravi Kacker

    MP48-11: Time to erectogenic effect of avanafil in a randomized, placebo-controlled trial
    Wayne J.G. Hellstrom

    Subscribe to Urology Times to get monthly news from the leading news source for urologists.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results